statin and inflamatio
Phase 3
- Conditions
- evels of inflammatory markers.????? ?????? ?? ?????? ????
- Registration Number
- IRCT20190903044682N1
- Lead Sponsor
- eyshabour University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
Acute coronary syndrome based on clinical signs and ECG and serum markers
Exclusion Criteria
renal failure
Liver failure
Immunosuppressants, corticosteroids or potent inhibitors of cytochrome P450 3A4, pentoxifylline, silostazole, glucosamine, berberine barberry extract
Having underlying inflammatory or infectious diseases
Left Schiff's Leukostosis
TG>400
CHF with NYHA III or IV
Having a history of diseases that cause malabsorption syndromes
Uncontrolled blood pressure
Evidence of endocrine or metabolic disease affecting lipid profile
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood levels of inflammatory markers. Timepoint: Before starting the study and 60 days later beginning. Method of measurement: Laboratory measurement by ELISA.
- Secondary Outcome Measures
Name Time Method ipid profile. Timepoint: Before the intervention and at the end of the intervention. Method of measurement: Laboratory measurement with Pars test kit with Autoanalyzer bt 3000.;Blood levels of inflammatory markers. Timepoint: Before the intervention and at the end of the intervention. Method of measurement: Laboratory tests.